Company: CERO
Filing Date: 2025-01-14
Form Type: 424B3
Source: 0001213900-25-003434
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-14
Form: 424B3
Chunk 4
---
 company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.02 Unregistered Sales of Equity Securities

On January 6, 2025, a holder
of warrants (“Preferred Warrants”) to purchase shares of Series A Preferred Stock, par value $0.0001 per share (“Series
A Preferred Stock”) of CERo Therapeutics Holdings, Inc. (the “Company”), exercised 625 Preferred Warrants for shares
of Series A Preferred Stock with an aggregate stated value of $625,000, at an exercise price of $800 per share (the “Warrant Exercises”),
reflecting the 20% original issue discount applicable to the issuance of shares of Series A Preferred Stock relative to the stated value
thereof. The Company received $500,000 of cash proceeds from the Warrant Exercises. Such holder converted the shares of Series A Preferred
Stock into an aggregate of 16,385,275 shares of common stock, par value $0.0001 per share (“Common Stock”) of the Company.
The receipt of such proceeds was included in the cash balance of the Company as of January 7, 2025 previously reported on a Current Report
on Form 8-K. In connection therewith, on January 6, 2025, the Company issued warrants to purchase an aggregate of 16,385,275 shares of
Common Stock, with an exercise price of $0.0582 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025,
to such holder as a condition to the Warrant Exercises thereby. Such shares were issued in reliance upon the exemption from registration
set forth in Section 4(a)(2) of the Securities Act of 1933, as amended.

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

| Date: January 10, 2025 | CERO THERAPEUTICS HOLDINGS, INC. |                         |
|:-----------------------|:---------------------------------|:------------------------|
|                        | By:                              | /s